| Literature DB >> 21152334 |
Eric Fombonne, Sara Quirke, Arlene Hagen.
Abstract
The aims of this article are to provide an up-to-date review of the methodological features and substantive results of published epidemiological surveys of the prevalence of pervasive developmental disorders (PDD). This article updates previous reviews (1, 2) with the inclusion of new studies made available since then. The specific questions addressed inthis article are: a) how are cases of PDD defined and identified in epidemiological surveys?; b) what are the best estimates for the prevalence of autism and related pervasive developmental disorders considering the methodological implications of the surveys, and c) what interpretation can be given to time trends observed in prevalence rates of PDDs given the hypothesized secular increase in PDDs?Entities:
Year: 2009 PMID: 21152334 PMCID: PMC2997266
Source DB: PubMed Journal: Mcgill J Med ISSN: 1201-026X
Prevalence surveys of autistic disorder
| Authors | Prevalence
| ||||||
|---|---|---|---|---|---|---|---|
| 1966 | Lotter (41) | UK | 78,000 | 8-10 | Rating scale | 4.1 | 2.7 ; 5.5 |
| 1970 | Brask (42) | Denmark | 46,500 | 2-14 | Clinical | 4.3 | 2.4 ; 6.2 |
| 1970 | Treffert (43) | USA | 899,750 | 3-12 | Kanner | 0.7 | 0.6 ; 0.9 |
| 1976 | Wing et al. (18) | UK | 25,000 | 5-14 | 24 items rating scale of Lotter | 4.8 | 2.1 ; 7.5 |
| 1982 | Hoshino et al. (17) | Japan | 609,848 | 0-18 | Kanner“s criteria | 2.33 | 1.9 ; 2.7 |
| 1983 | Bohman et al. (44) | Sweden | 69,000 | 0-20 | Rutter criteria | 5.6 | 3.9 ; 7.4 |
| 1984 | McCarthy et al. (45) | Ireland | 65,000 | 8-10 | Kanner | 4.3 | 2.7 ; 5.9 |
| 1986 | Steinhausen et al. (46) | Germany | 279,616 | 0-14 | Rutter | 1.9 | 1.4 ; 2.4 |
| 1987 | Burd et al. (47) | USA | 180,986 | 2-18 | DSM-III | 3.26 | 2.4 ; 4.1 |
| 1987 | Matsuishi et al. (48) | Japan | 32,834 | 4-12 | DSM-III | 15.5 | 11.3 ; 19.8 |
| 1988 | Tanoue et al. (49) | Japan | 95,394 | 7 | DSM-III | 13.8 | 11.5 ; 16.2 |
| 1988 | Bryson et al. (50) | Canada | 20,800 | 6-14 | New RDC | 10.1 | 5.8 ; 14.4 |
| 1989 | Sugiyama & | Japan | 12,263 | 3 | DSM-III | 13.0 | 6.7 ; 19.4 |
| 1989 | Cialdella & Mamelle (52) | France | 135,180 | 3-9 | DSM-III like | 4.5 | 3.4 ; 5.6 |
| 1989 | Ritvo et al. (53) | USA | 769,620 | 3-27 | DSM-III | 2.47 | 2.1 ; 2.8 |
| 1991 | Gillberg et al. (36) | Sweden | 78,106 | 4-13 | DSM-III-R | 9.5 | 7.3 ; 11.6 |
| 1992 | Fombonne & du Mazaubrun (39) | France | 274,816 | 9 & 13 | Clinical-ICD-10 like | 4.9 | 4.1 ; 5.7 |
| 1992 | Wignyosumarto et al. (54) | Indonesia | 5,120 | 4-7 | CARS | 11.7 | 2.3 ; 21.1 |
| 1996 | Honda et al. (55) | Japan | 8,537 | 5 | ICD-10 | 21.08 | 11.4 ; 30.8 |
| 1997 | Fombonne et al. (40) | France | 325,347 | 8-16 | Clinical ICD-10-like | 5.35 | 4.6 ; 6.1 |
| 1997 | Webb et al. (33) | UK | 73,301 | 3-15 | DSM-III-R | 7.2 | 5.3 ; 9.3 |
| 1997 | Arvidsson et al. (56) | Sweden | 1,941 | 3-6 | ICD-10 | 46.4 | 16.1 ; 76.6 |
| 1998 | Sponheim & Skjeldal (57) | Norway | 65,688 | 3-14 | ICD-10 | 5.2 | 3.4 ; 6.9 |
| 1999 | Taylor et al. (22) | UK | 490,000 | 0-16 | ICD-10 | 8.7 | 7.9 ; 9.5 |
| 1999 | Kadesjö et al. (70) | Sweden (Central) | 826 | 6.7-7.7 | DSM-III-R/ICD-10 Gillberg“s criteria (Asperger syndrome) | 72.6 | 14.7 ; 130.6 |
| 2000 | Baird et al. (58) | UK | 16,235 | 7 | ICD-10 | 30.8 | 22.9 ; 40.6 |
| 2000 | Powell et al. (59) | UK | 25,377 | 1-5 | Clinical/ | 7.8 | 5.8 ; 10.5 |
| 2000 | Kielinen et al. (31) | Finland | 27,572 | 5-7 | DSM-IV | 20.7 | 15.3 ; 26.0 |
| 2001 | Bertrand et al. (60) | USA | 8,896 | 3-10 | DSM-IV | 40.5 | 28.0 ; 56.0 |
| 2001 | Fombonne et al. (24) | UK | 10,438 | 5-15 | DSM-IV/ | 26.1 | 16.2 ; 36.0 |
| 2001 | Magnússon and Saemundsen (32) | Iceland | 43,153 | 5-14 | Mostly ICD-10 | 13.2 | 9.8 ; 16.6 |
| 2001 | Chakrabarti & Fombonne (37) | UK (Midlands) | 15,500 | 2.5-6.5 | ICD10/ | 16.8 | 10.3 ; 23.2 |
| 2001 | Davidovitch et al. (61) | Israel | 26,160 | 7-11 | DSM-III-R/ | 10.0 | 6.6;14.4 |
| 2002 | Croen et al. (7) | USA | 4,950,333 | 5-12 | CDER «Full syndrome» | 11.0 | 10.7;11.3 |
| 2002 | Madsen et al. (11) | Denmark | 63,859 | 8 | ICD-10 | 7.2 | 5.0 – 10.0 |
| 2004 | Tebruegge et al. (62) | UK | 2,536 | 8-9 | ICD-10 | 23.7 | 9.6 ; 49.1 |
| 2005 | Chakrabarti & Fombonne (38) | UK (Midlands) | 10,903 | 4-7 | ICD-10/DSM-IV | 22.0 | 14.4 ; 32.2 |
| 2005 | Barbaresi et al (63) | USA, Minnesota | 37,726 | 0-21 | DSM-IV | 29.7 | 24.0; 36.0 |
| 2005 | Honda et al (64) | Japan | 32,791 | 5 | ICD-10 | 37.5 | 31.0; 45.0 |
| 2006 | Fombonne et al. (9) | Canada (Quebec) | 27,749 | 5-17 | DSM-IV | 21.6 | 16.5 ; 27.8 |
| 2006 | Gillberg et al. (65) | Sweden | 32,568 | 7-12 | Gillberg“s criteria | 35.3 | 29.2 ; 42.2 |
| 2006 | Baird et al. (20) | UK | 56,946 | 9-10 | ICD-10 | 38.9 | 29.9; 47.8 |
| 2007 | Ellefsen et al. (66) | Denmark | 7,689 | 8-17 | ICD-10 | 16.0 | 7.0; 25.0 |
| 2007 | Oliveira et al. (67) | Portugal | 67,795 | 6-9 | DSM-IV | 16.7 | 14.0; 20.0 |
| 2007 | Latif and Williams (68) | UK | 39,220 | 0-17 | Kanner | 12.7 | 9.0;17.0 |
| 2008 | Williams et al. (69) | UK | 14,062 | 11 | ICD-10 | 21.6 | 13.9 ; 29.3 |
| 2009 | Lazoff et al. (10) | Canada | 23,662 | 5 – 17 | DSM-IV | 26.2 | 19.7 ; 32.7 |
Newer epidemiological surveys of PDDs
| References | Country | Size | Age | Prevalence/10,000 | 95% CI |
|---|---|---|---|---|---|
| Baird et al, 2000 (58) | UK | 16,235 | 7 | 57.9 | 46.8 – 70.9 |
| Bertrand et al, 2001 (60) | USA | 8,896 | 3-10 | 67.4 | 51.5 – 86.7 |
| Chakrabarti & Fombonne, 2001 (37) | UK | 15,500 | 4-7 | 61.9 | 50.2 – 75.6 |
| Madsen et al, 2002 (11) | Denmark | --- | 8 | 30.0 | --- |
| Scott et al, 2002 (70) | UK | 33,598 | 5-11 | 58.3 | 50 -67 |
| Yeargin-Allsopp et al, 2003 (72) | USA | 289,456 | 3-10 | 34.0 | 32 – 36 |
| Gurney et al, 2003 (8) | USA | --- | 8 – 10 | 52.0 | --- |
| Icasiano et al, 2004 (73) | Australia | ≈ 54,000 | 2-17 | 39.2 | --- |
| Tebruegge et al., 2004 (62) | UK | 2,536 | 8-9 | 82.8 | 51.3 – 126.3 |
| Chakrabarti & Fombonne, 2005 (38) | UK | 10,903 | 4-6 | 58.7 | 45.2 – 74.9 |
| Baird et al, 2006 (20) | UK | 56,946 | 9-10 | 116.1 | 90.4 – 141.8 |
| Fombonne et al, 2006 (9) | Canada | 27,749 | 5–17 | 64.9 | 55.8 – 75.0 |
| Harrison et al, 2006 (34) | UK | 134,661 | 0-15 | 44.2 | 39.5 – 48.9 |
| Gillberg et al, 2006 (69) | Sweden | 32,568 | 7 12 | 80.4 | 71.3 – 90.3 |
| CDC, 2007a (12) | USA | 187,761 | 8 | 67.0 | --- |
| CDC, 2007b (13) | USA | 407,578 | 8 | 66.0 | 63 – 68 |
| Ellefsen et al, 2007 (66) | Denmark | 7,689 | 8-17 | 53.3 | 36 – 70 |
| Latif & Williams, 2007 (68) | UK | 39,220 | 0-17 | 61.2 | 54 – 69 |
| Wong et al, 2008 (74) | China | 4,247,206 | 0-14 | 16.1 (1986-2005) | --- |
| Nicholas et al, 2008 (75) | USA | 47,726 | 8 | 62.0 | 56 – 70 |
| Kawamura et al, 2008 (21) | Japan | 12,589 | 5-8 | 181.1 | 158.5 – 205.9 |
| Williams et al, 2008 (69) | UK | 14,062 | 11 | 61.9 | 48.8 – |
| Lazoff et al, 2009 (9) | Canada | 23,662 | 5-17 | 80.3 | 68.9-91.7 |
calculated by the author
these are the highest prevalences reported in this study of time trends. The prevalence in 10 year olds is for the 1991 birth cohort, and that for 8 year olds for the 1993 birth cohort. Both prevalences were calculated in the 2001-2002 school year.
estimated using a capture-recapture analysis, the number of cases used to calculate prevalence was estimated to be 596.
specific values for % with normal IQ and confidence intervals are available for each state prevalence